CeQur announced today that it closed a $100 million Series E financing round to support its mealtime insulin delivery technology. Horw, Switzerland-based CeQur develops the Simplicity mealtime insulin patch pump system. The wearable, disposable bolus insulin delivery system was developed as, essentially, a wearable insulin pen. CeQur began a pilot commercial launch for the FDA-cleared […]
Drug-Device Combinations
Sequel Med Tech chief medical officer explains why company is ‘excited about what’s ahead’
Sequel Med Tech has a habit of making waves at the American Diabetes Association’s annual Scientific Sessions event. In 2024, the Manchester, New Hampshire-based company was generating buzz following its entry into the automated insulin delivery market with twiist, its pump system, which had garnered FDA clearance in March of that year. At last year’s […]
Dexcom CEO Jake Leach talks Nutrisense acquisition, type 2 push, next-gen G8
Nearly halfway through 2026, the milestones are already stacking up for continuous glucose monitor (CGM) maker Dexcom (Nadsaq:DXCM). President and CEO Jake Leach took over the corner office in January. In the months that have followed, highlights include the unveiling of the next-generation G8 sensor system, the launch of the Flex sensor platform outside the […]
Terrestrial Bio data backs needle-free patch for GLP-1 delivery
Terrestrial Bio today shared new preclinical data demonstrating the translatability of its patch technology for delivering GLP-1 therapies. Boston-based Terrestrial (formerly Vaxess Technologies) shared findings at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Outcomes showed the translatability of the proprietary Tacterra MAP platform to deliver next-generation obesity therapies that involve co-delivery […]
Sequel Med Tech data supports twiist automated insulin delivery in type 2 diabetes
Sequel Med Tech today announced clinical findings supporting its twiist automated insulin delivery (AID) system in type 2 diabetes. twiist, which works with the twiist Loop algorithm, powered by Tidepool, directly measures the volume of insulin delivered with every microdose. The system offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system […]
Senseonics study supports Eversense 365 CGM with automated insulin delivery tech
Senseonics (NYSE:SENS) today announced real-world evidence supporting the performance of its Eversense 365 year-long CGM implant. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. Germantown, Maryland-based Senseonics said data […]
Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes
Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes. The CONNECT study evaluated the current-generation G7 continuous glucose monitor (CGM) in people with type 2 diabetes not using insulin. It compared this population to a routine care control group using self-monitoring of blood glucose. Researchers shared […]
Abbott studies reinforce DKA opportunity following dual sensor milestone
Abbott (NYSE:ABT) today announced new clinical data highlighting the importance of managing diabetic ketoacidosis (DKA). The medtech giant shared findings from multiple studies at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans that demonstrate sharp increases in DKA-related hospitalizations across all age groups with type 1 and type 2 diabetes nationwide. Abbott […]
Insulet data backs Omnipod 6, fully closed-loop AID systems
Insulet (Nasdaq:PODD) today announced new clinical findings for its next-generation Omnipod 6 and fully closed-loop algorithm. The company shared results from its STRIVE pivotal trial and EVOLUTION 3 feasibility study. Investigators presented the outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Findings demonstrated meaningful improvements in glucose control for people […]
Tidepool data highlights automated insulin delivery algorithm enhancements, women’s health initiative
Tidepool has new clinical insights and research initiatives related to diabetes management and automated insulin delivery (AID) technology. Palo Alto, California-based Tidepool is a non-profit diabetes data management group. It developed the FDA-cleared Tidepool Loop, a “do-it-yourself” (DIY) AID system. The hybrid, closed-loop AID app has compatibility with multiple insulin pumps and continuous glucose monitors. […]
